Drug intelligence / Profile preview

TRTL-913

Development stage: Phase 2
Lead developer: Tortugas Neuroscience
Modality: Small Molecules

Overview

TRTL-913 is a small molecule positive allosteric modulator (PAM) of GABA receptors, currently in preclinical development by Tortugas Neuroscience. It is being investigated for the treatment of tinnitus. The drug's mechanism involves enhancing inhibitory GABAergic signaling in the brain, which is hypothesized to counteract the aberrant neural activity associated with tinnitus.

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on TRTL-913.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRTL-913.

Explore the full profile